Linsitinib, Free base | 2294

A potent, small-molecule dual insulin-like growth factor-1 receptor (IGF-1R)/insulin receptor (IR) kinase inhibitor. Inhibits IGF-1R and IR kinases with IC₅₀ values of 35 nM and 75 nM, respectively. Linsitinib selectively blocks the autophosphorylation of both human IGF-1R and IR, inhibits the proliferation of a variety of tumor cell lines in vitro, and displays robust in vivo anti-tumor efficacy in an IGF-1R-driven xenograft model when administered orally.

Linsitinib is a potent, small-molecule dual insulin-like growth factor-1 receptor (IGF-1R)/insulin receptor (IR) kinase inhibitor. Inhibits IGF-1R and IR kinases with IC₅₀ values of 35 nM and 75 nM, respectively

2294 | Linsitinib, Free base DataSheet

Alternate Name/Synonyms: (1S,3S)-3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl)-1-methylcyclobutanol; OSI-906; OSI 906AA

Appearance: White to off-white solid

Formulation: N/A

CAS Number: 867160-71-2

Structure Available?: Yes

Peptide sequence: No

Salt Form: No

Molecular Formula: C₂₆H₂₃N₅O

Molecular Weight: 421.49

Cell-Permeable?: Yes

Purity: ≥99% by HPLC

Solubilities: DMSO (~50 mg/ml) or Ethanol (~3 mg/ml)

Handling: Protect from air and light

Country of Origin: USA

Tag Line: A potent, dual insulin-like growth factor-1 receptor (IGF-1R)/insulin receptor (IR) kinase inhibitor.

MDL Number: MFCD12912153

PubChem CID: 11640390

SMILES: CC1(CC(C1)C2=NC(=C3N2C=CN=C3N)C4=CC5=C(C=C4)C=CC(=N5)C6=CC=CC=C6)O

InChi: InChI=1S/C26H23N5O/c1-26(32)14-19(15-26)25-30-22(23-24(27)28-11-12-31

InChi Key: PKCDDUHJAFVJJB-UHFFFAOYSA-N